Head-To-Head Comparison: Aytu BioPharma (NASDAQ:AYTU) & Harrow (NASDAQ:HROW)

Aytu BioPharma (NASDAQ:AYTU) and Harrow (NASDAQ:HROW) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares Aytu BioPharma and Harrow’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Harrow	-13.51%	-38.00%	-3.37%

Earnings and Valuation

This table compares Aytu BioPharma and Harrow”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38 million	0.36	-$13.56 million	($4.58)	-0.49
Harrow	$272.30 million	4.74	-$5.14 million	($1.00)	-34.45

Harrow has higher revenue and earnings than Aytu BioPharma. Harrow is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Aytu BioPharma has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Aytu BioPharma and Harrow, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1	1	3	0	2.40
Harrow	1	2	8	0	2.64

Aytu BioPharma presently has a consensus price target of $10.75, indicating a potential upside of 382.06%. Harrow has a consensus price target of $66.71, indicating a potential upside of 93.66%. Given Aytu BioPharma’s higher possible upside, equities analysts clearly believe Aytu BioPharma is more favorable than Harrow.

Insider & Institutional Ownership

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Harrow beats Aytu BioPharma on 11 of the 14 factors compared between the two stocks.

About Aytu BioPharma

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.